Construction Business Review Conferences
The 6th iPSC Drug Development Summit convenes senior biopharma leaders in Boston to address translational strategy, CMC, and scalable manufacturing for iPSC therapies, with insights from Astellas, BlueRock, Aspen, Vertex, and others advancing clinical programs.
6th Annual Oligonucleotides for CNS Summit will bring together 160+ experts across CNS biology, oligo chemistry, RNA science, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative, neuromuscular, rare, epileptic, and neurodevelopmental disorders. This summit uniquely connects stakeholders at the intersection of oligonucleotides and CNS. Join leaders from Eli Lilly, Dyne Therapeutics, Creyon Bio, and more for three days of collaboration to accelerate RNA-targeted CNS therapies.
As the first industry-led forum dedicated to transforming the Myasthenia Gravis (MG), CIDP, GBS and MMN treatment landscapes, the Autoimmune Neuromuscular & Nerve Disorders Drug Development Summit (July 21-23, 2026 | Boston, MA) will bring together leading biopharma experts to tackle the mechanistic and translational challenges shaping this rapidly evolving space. Uniting 65+ end-to-end biotech and pharma professionals to strengthen translational research and address key challenges in disease biology, patient stratification, and biomarker validation, attendees will explore the evolving landscape of FcRn inhibition, complement targeting, and B-cell modulation through expert-led presentations, panel discussions, and dedicated workshops.
The 6th mRNABased Therapeutics Summit (Boston, MA | July 20–22, 2026) unites over 250 global biopharma and regulatory bodies, including the FDA, EMA, and MHRA. Attending companies include Moderna, BioNTech, Pfizer, Sanofi, and AstraZeneca. Covering cutting-edge science, regulatory strategy, AI-driven design, and CMC innovation, the event provides a collaborative forum to address key challenges and accelerate the development of next-generation mRNA development beyond vaccines.
The 2nd Operationalize: Expanded Access Programs Summit West arrives at a critical moment. Purpose-built for West Coast biotech and pharma teams, this summit brings together senior leaders across Access, Medical Affairs, Clinical Operations, Regulatory, and Clinical Supply to share how EAPs are being designed, governed, and scaled in today’s environment. Over three focused days, the summit tackles the most pressing questions facing EAP teams in 2026 - from navigating evolving U.S. and global regulatory expectations, to enabling providers and patient advocates, designing post-trial access strategies, managing long-duration and rare disease programs, and applying real-world insights without slowing access.
The in vivo cell engineering and gene editing landscape is entering a pivotal moment as investment from leaders such as Kite Pharma, Eli Lilly, AstraZeneca, and AbbVie accelerates and reshapes the competitive landscape. With ex vivo approaches facing high costs, long turnaround times, and conditioning burdens, developers are moving rapidly toward in vivo therapies that offer greater accessibility, faster clinical timelines, and broader therapeutic reach. The momentum is reinforced by emerging innovators securing significant funding, including recent successes such as Azalea Therapeutics.
The 5th Liquid Biopsy for Precision Oncology Summit East Coast returns as your definitive forum harnessing the power of liquid biopsies to drive smarter, better and more precise clinical decisions for patients in need. Expect to join a wealth of liquid biopsy KOL’s including senior representatives at Bristol Myers Squibb, Pfizer, AstraZeneca and industry-leading diagnostic providers such as Foundation Medicine, Guardant Health, Natera, Personalis, Myriad Genetics, Tempus, Hologic and BioIVT. Seize the opportunity to enhance your understanding, gain actionable takeaways and hear directly from senior biopharma experts to develop stronger ctDNA, MRD and next-generation biomarkers and redefine the future of clinical trials for oncology drug development.
Join the 10th Microbiome AgBioTech Summit, bringing together leaders in microbial discovery, agbiological innovation, formulation, fermentation, and field validation to advance next‑generation biological solutions for modern agriculture.
The 5th Circular & Self-Amplifying RNA Therapeutics Summit unites biotech and pharma leaders to advance circRNA and saRNA into durable, IND‑ready medicines, tackling challenges across delivery, immunogenicity, CMC, and translation.
The 7th TCR‑Based Therapies Summit is your pivotal industry-focused meeting uniting global leaders advancing T‑cell receptor–based cell and biologic therapies. Taking place this May, in Boston, we will delve into the field’s most urgent scientific, translational, and commercial challenges, to support the progression of durable, scalable TCR therapies to the clinic and beyond.
